Skip to main content
Article thumbnail
Location of Repository

Memantine combined with an acetyl cholinesterase inhibitor – hope for the future?

By Chris Fox, Ian D Maidment, Malaz Boustani and Cornelius Katona
Topics: Commentary
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2004). [AD2000] AD2000 Collaborative Group.
  2. (2004). Acetylcholinesterase and its inhibition in Alzheimer disease.
  3. (2003). Adverse nondrug reactions [online].
  4. (1997). An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease. Alzh Dis Assoc Disord,
  5. (2005). and Drug Administration
  6. (1971). Beoordelingsschaal voor Oudere Patienten (BOP). Deventer, The Netherlands: Van Loghum Slaterus.
  7. (2004). Cholinesterase inhibitors: new roles and therapeutic alternatives. Pharmacol Res,
  8. (2002). Dementia epidemiology.
  9. (2006). Drug treatment for Alzheimer’s disease: the way forward.
  10. (2005). Effects of memantine and donepezil on amyloid beta-induced memory impairment in a delayed-matching to position task in rats.
  11. (1999). EUROCARE: a crossnational study of co-resident spouse carers for people with Alzheimer’s disease: I-Factors associated with carer burden.
  12. (2000). Galantamine is an allosterically potentiating ligand of the human alpha 4/ beta 2 nAChR. Acta Neurol Scand,
  13. (2003). Glutamatergic systems in Alzheimer’s disease.
  14. (2003). Good practice in appraising trials. International Guideline and Approaches. Int Psychogeriatr, 15(Suppl 2):S27.
  15. (2002). Impact of Alzheimer’s disease, 2000-2050: potential implication of treatment advances. Annu Rev Public Health,
  16. (2003). Memantine in moderate-tosevere Alzheimer’s disease.
  17. (2004). Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil – a randomized controlled trial.
  18. (1975). Mini-mental state: a practical method for grading the mental state of patients for the clinician.
  19. Mobius SJ 2003. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy.
  20. (2005). New Clinical Drug Evaluation Unit 45th Annual General Meeting.
  21. (2000). No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use. Life Sci,
  22. (2003). Pharmaceutical industry sponsorship and research outcome and quality: systematic review.
  23. (1994). Psychiatric Association
  24. (2003). Res, 12:189–98.Neuropsychiatric Disease and Treatment 2006:2(2) 125 Memantine and cholinesterase combination [FLI] Forest Laboratories Inc.
  25. (2004). Safety, tolerability and caregiver’s impressions of combination therapy with donepezil and memantine for the treatment of Alzheimer’s disease [abstract]. Neurobiol Aging,
  26. (2003). Screening for dementia. systematic evidence review [online].
  27. (1994). Severe impairment battery: a neuropsychological test for severely demented patients.
  28. (2004). Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer’s disease.
  29. (2001). Stage 11 conducting the review phase 5 study quality assessment York Centre for Reviews and Dissemination.
  30. (1988). Statistical power analysis for the behavioral sciences. 2nd ed.
  31. (1982). The cholinergic hypothesis of geriatric memory dysfunction.
  32. (1994). The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.
  33. (1991). Therapy of the cognitive deficit in Alzheimer’s disease: the cholinergic system.
  34. (2004). Tolerability and caregiver’s impressions of combination therapy with galantamine and memantine for the treatment of Alzheimer’s disease [abstract]. Neurobiol Aging,
  35. (1997). Validity and reliability of the Alzheimer’s Disease Cooperative Study – Clinical Global Impression of Change. Alzheimer Dis Assoc Disord,

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.